Drug major Cipla, which is not new to churn in its top deck, on Friday saw another exit when its global chief financial officer Kedar Upadhye resigned.
In 2020, Nikhil Chopra, the chief executive of Cipla’s India business and two others, including Nikhil Lalwani, head of India prescription business, and Kunal Khanna, the cluster head of chronic and emerging business development, had resigned due to personal reasons. Before that R. Ananthanarayanan who was the global chief operating officer had quit to join Strides.
In a regulatory filing, Cipla said Upadhye has resigned from the position of global chief financial officer to pursue his professional aspirations beyond pharmaceutical and the healthcare sector. Before joining Cipla, Upadhye was at Dr Reddy’s Laboratories where he was the vice-president, global generics finance and head of investor relations.
The company added that Upadhye will serve his full notice period of three months — up to close of business hours of May 3, 2022 and will continue in his current role as global chief financial officer and key managerial personnel until relieved. Cipla pointed out that the board will announce the successor in due course.
“The last five years at Cipla have been extremely gratifying. Under the guidance of Samina Hamied, Umang Vohra and the entire management council we have delivered across our strategic priorities,’’ Upadhye said.